drugset
drugset / Trial / NCT03389685

Can PRP Reduce Pro-Inflammatory Biomarkers Following ACL Injury

NCT03389685 ↗

Phase 2 Withdrawn NYU Langone Health
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this single-center, double-blinded randomized control trial with prospective data collection is to assess the ability of platelet rich plasma (PRP) treatment to reduce the level of pro-inflammatory synovial fluid biomarkers following an acute anterior cruciate ligament (ACL) tear. The study will collect and analyze synovial fluid of patients presenting with an acute anterior cruciate ligament (ACL) tear with a second synovial fluid sampling at the time of surgery. It will compare synovial fluid biomarker levels between those receiving an intra-articular Platelet Rich Plasma (PRP) injection versus an intra-articular saline injection serving as a control. Post-operative clinical outcomes will also be assessed, including post-operative pain levels, incidence of post-operative knee stiffness and patient reported outcome scores.

Timeline

Start
2018-09-09
Primary completion
2024-02
Completion
2024-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Platelet Rich Plasma Other / unclassified — Other

Indications

No indication recorded.